Clinical observation and therapeutic evaluation of intravenous pump of recombinant human endostatin combined with TP regimen in treating patients with advanced ovarian cancer
Clinical observation and therapeutic evaluation of intravenous pump of recombinant human endostatin combined with TP regimen in treating patients with advanced ovarian cancer作者机构：Department of Internal Medicine-Oncology Henan Cancer Hospital The Affiliated Cancer Hospital of Zhengzhou UniversityZhengzhou 450000 China
出 版 物：《Chronic Diseases and Translational Medicine》 (慢性疾病与转化医学（英文版）)
年 卷 期：2015年第1卷第3期
页 面：-页
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
主 题：Ovarian cancer Recombinant human endostatin Intravenous pump Vascular endothelial growth factor Angiogenesis
摘 要：Objectives: To observe the curative effects and adverse reactions of recombinant human (rh)-endostatin injection combined with a TP regimen for treating patients with advanced ovarian ***: Fifty-four patients with pathologically confirmed ovarian cancer were randomly divided into a combined treatment (intravenous pump of rh-endostatin + TP regimen) group and a control (single chemotherapy) group, twenty-seven patients in each *** patients were given a conventional CT *** level of vascular endothelial growth factor (VEGF), the size of tumor before treatment, after 2 cycles and after 4 cycles of treatment were determined for the comparison of curative effects and adverse ***: The effective rate was 37.0％ (10/27) and disease control rate was 63.0％ (17/27) in the combined treatment group after 2 cycles of *** effective rate was 25.9％ (7/27) and disease control rate was 63.0％ (17/27) in the control *** comparison between these two groups showed no significant differences (P 0.05).The effective rate was 63.0％ (17/27) and disease control rate was 92.6％ (25/27) in the combined treatment group after 4 cycles of *** effective rate was 29.6％ (8/27) and disease control rate was 63.0％ (17/27) in the control *** effective rate and disease control rate between these two groups after 4 cycles of treatment showed significant differences (P 0.05).The incidences of cardiovascular toxicity, myelosuppression, sore muscles and joints, alopecia and gastrointestinal reaction was not significantly different between two groups (P 0.05).Conclusion: The pump delivery of rh-endostatin can down-regulate the expression of VEGF in ovarian cancer and has the better curative effect and slighter adverse *** 2015, Chinese Medical Association *** and hosting by Elsevier *** behalf of KeAi Communications Co., *** is an open access article under the CC BY-NC-ND license (http://creati
维普期刊数据库
同方期刊数据库